Lexeo Therapeutics

LXEO · NASDAQ

$3.02+$0.26 (+9.42%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.76

LXEO analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy1
Buy5
Hold0
Underperform0
Sell0

12-month price target · 12 analysts

Average $21.99 (+628.0% upside)

Low: $15.15
Now: $3.02
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

LXEO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Leerink Partners	Sep 23, 2026	Maintains	Outperform	$15.00	35%
JP Morgan	Jun 25, 2026	Maintains	Overweight	$12.00 → $9.00	44%
Chardan Capital	May 11, 2026	Maintains	Buy	$17.00	43%
Chardan Capital	Jan 13, 2026	Maintains	Buy	$17.00	43%
HC Wainwright & Co.	Jan 13, 2026	Maintains	Buy	$13.00 → $10.00	32%
Raymond James	Dec 18, 2025	Initiates	Strong Buy	$25.00	51%
Chardan Capital	Dec 11, 2025	Maintains	Buy	$17.00	43%
Cantor Fitzgerald	Dec 1, 2025	Initiates	Overweight	$19.00	41%
Cantor Fitzgerald	Nov 20, 2025	Initiates	Overweight	$19.00	41%
Chardan Capital	Nov 5, 2025	Maintains	Buy	$17.00	43%

The case for and against

Updated Oct 16, 2026

Bull case

Lexeo Therapeutics is attractive because LX2006 is showing durable, clinically meaningful cardiac benefit in Friedreich ataxia, with 18% and 23% mean LVMI reductions at 6 and 12 months in patients with abnormal baseline LVMI, plus no Grade 3+ treatment-related SAEs to date across 17 dosed participants. The neurologic signal also strengthens the case, as mean mFARS improved versus a matched natural history cohort with statistical significance and an annualized progression difference of 2.3 points per year, supporting broader long-term differentiation. With $227.6 million of cash as of 31 March 2026, runway into 2028, and additional optionality from Mantle programs and LX2020, the company appears well positioned to advance a de-risked platform toward pivotal data and multiple shots on goal.

Bear case

Lexeo Therapeutics is weighed down by a highly uncertain commercialization path, as cardiac gene therapies may face payer and reimbursement hurdles, limited physician and patient adoption, and competition from more convenient small-molecule or other genetic medicine alternatives. Its pipeline also carries elevated clinical, regulatory, and manufacturing risk because early proof-of-concept in FA and PKP2 may not replicate in later studies, the FDA could demand longer and more capital-intensive pivotal trials, and AAV-based programs remain complex and difficult to scale reliably. Financially, the company may need additional equity funding before profitability, with dilution already reflected in a modeled net cash value of $2.42 NPV/share, while preclinical Mantle assets face added uncertainty in the current commercial landscape in Friedrich's Ataxia.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.